4.5 Article

Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people

期刊

EUROPEAN JOURNAL OF HEART FAILURE
卷 19, 期 9, 页码 1119-1127

出版社

WILEY
DOI: 10.1002/ejhf.709

关键词

Heart failure; Epidemiology; Prognosis; Acute hospital admission; Primary care; Electronic health records

资金

  1. Genetic Cardiomyopathy PLN
  2. Wellcome Trust [0938/30/Z/10/Z]
  3. Netherlands Heart Foundation [2014T001]
  4. UCL Hospitals NIHR Biomedical Research Centre
  5. Medical Research Council
  6. Arthritis Research UK
  7. British Heart Foundation
  8. Cancer Research UK
  9. Chief Scientist Office
  10. Economic and Social Research Council
  11. Engineering and Physical Sciences Research Council
  12. National Institute for Health Research
  13. Wellcome Trust
  14. National Institute for Social Care and Health Research
  15. British Heart Foundation [FS/14/76/30933] Funding Source: researchfish
  16. Economic and Social Research Council [ES/L007517/1] Funding Source: researchfish
  17. Medical Research Council [MR/L01629X/1, MR/K006584/1] Funding Source: researchfish
  18. National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish
  19. ESRC [ES/L007517/1] Funding Source: UKRI
  20. MRC [MR/L01629X/1] Funding Source: UKRI

向作者/读者索取更多资源

Aims The prognosis of patients hospitalized for worsening heart failure (HF) is well described, but not that of patients managed solely in non-acute settings such as primary care or secondary outpatient care. We assessed the distribution of HF across levels of healthcare, and assessed the prognostic differences for patients with HF either recorded in primary care (including secondary outpatient care) (PC), hospital admissions alone, or known in both contexts Methods and results This study was part of the CALIBER programme, which comprises linked data from primary care, hospital admissions, and death certificates for 2.1 million inhabitants of England. We identified 89 554 patients with newly recorded HF, of whom 23 547 (26%) were recorded in PC but never hospitalized, 30 629 (34%) in hospital admissions but not known in PC, 23 681 (27%) in both, and 11 697 (13%) in death certificates only. The highest prescription rates of ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists was found in patients known in both contexts. The respective 5-year survival in the first three groups was 43.9% [95% confidence interval (CI) 43.2-44.6%], 21.7% (95% CI 21.1-22.2%), and 39.8% (95% CI 39.2-40.5%), compared with 88.1% (95% CI 87.9-88.3%) in the age-and sex-matched general population. Conclusion In the general population, one in four patients with HF will not be hospitalized for worsening HF within a median follow-up of 1.7 years, yet they still have a poor 5-year prognosis. Patients admitted to hospital with worsening HF but not known with HF in primary care have the worst prognosis and management. Mitigating the prognostic burden of HF requires greater consistency across primary and secondary care in the identification, profiling, and treatment of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据